Clinical trials
Observational Cerebral Hemorrhage trials with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
43 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2008 | 1 |
| 2009 | 1 |
| 2012 | 3 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 3 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 4 |
| 2020 | 3 |
| 2021 | 5 |
| 2022 | 5 |
| 2023 | 3 |
| 2024 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 43 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 3 |
| University College, London | 3 |
| Beijing Neurosurgical Institute | 2 |
| Capital Medical University | 2 |
| Insel Gruppe AG, University Hospital Bern | 2 |
| National Taiwan University Hospital | 2 |
| Soroka University Medical Center | 2 |
| Xiangya Hospital of Central South University | 2 |
| Aneurin Bevan University Health Board | 1 |
| Assiut University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Cerebral Hemorrhage | 43 |
| Subarachnoid Hemorrhage | 14 |
| Ischemic Stroke | 12 |
| Brain Injuries, Traumatic | 11 |
| Stroke | 9 |
| Cerebral Infarction | 5 |
| Ischemic Attack, Transient | 5 |
| Angina, Stable | 3 |
| Angina, Unstable | 3 |
| Aortic Aneurysm, Abdominal | 3 |
Trials
Showing 1 to 25 of 43. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.